Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
12 Juli 2023 - 1:30PM
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the
“Company”), a clinical-stage biopharmaceutical company leveraging
its extensive virology expertise to develop novel therapeutics that
target specific viral diseases, today announced the appointment of
Melissa V. Rewolinski, PhD, to its board of directors, effective
July 12, 2023.
“We are excited to welcome Dr. Rewolinski to the
Arbutus Board,” said William Collier, President and Chief Executive
Officer of Arbutus. “Dr. Rewolinski brings more than 20 years of
strategic, operational and drug development experience within the
pharmaceutical industry. We look forward to relying on her counsel
and expertise as we continue to advance our pipeline of assets
directed towards a functional cure for HBV and novel treatment
options for coronavirus.”
Dr. Rewolinski currently serves as principal of
MVR Consulting, where she specializes in providing counsel to small
and mid-size biotechnology and pharmaceutical companies. Earlier
she held a number of senior level R&D positions for Intercept,
rising to Senior Vice President, Head of Technical Operations, and
member of the Executive Team. Previously, she served as Senior
Director, Development for Amira Pharmaceuticals, and before that as
a Chemical Development Group Leader and a Pharmaceutical Sciences
Project Team Leader for Pfizer Global R&D. Dr. Rewolinski began
her career at Pharmacia & Upjohn as a post-doctoral research
scientist. She currently serves as a board member for Lannett
Company, Inc., and American Type Culture Collection (ATCC). Dr.
Rewolinski earned a doctorate degree in organic chemistry and
Bachelor of Science degree in chemistry, magna cum laude,
from Rice University.
Dr. Rewolinski, commented, “This is an exciting
time to join the Board of Arbutus. I look forward to working with
my fellow Board members to support Arbutus in its continued efforts
to develop treatments for HBV and coronaviruses.”
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to develop novel therapeutics that target
specific viral diseases. Our current focus areas include Hepatitis
B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV,
we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and
an oral RNA destabilizer to potentially identify a combination
regimen with the aim of providing a functional cure for patients
with chronic HBV by suppressing viral replication, reducing surface
antigen and reawakening the immune system. We believe our lead
compound, AB-729, is the only RNAi therapeutic with evidence of
immune re-awakening. AB-729 is currently being evaluated in
multiple phase 2 clinical trials. We also have an ongoing drug
discovery and development program directed to identifying novel,
orally active agents for treating coronaviruses, (including
SARS-CoV-2), for which we have nominated a compound and have begun
IND-enabling pre-clinical studies. In addition, we are also
exploring oncology applications for our internal PD-L1 portfolio.
For more information, visit www.arbutusbio.com.
Forward-Looking Statements and
Information
This press release contains forward-looking
statements within the meaning of the Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
and forward-looking information within the meaning of Canadian
securities laws (collectively, forward-looking statements).
Forward-looking statements in this press release include statements
about our future development plans for our product candidates.
With respect to the forward-looking statements
contained in this press release, Arbutus has made numerous
assumptions regarding, among other things: the effectiveness and
timeliness of preclinical studies and clinical trials, and the
usefulness of the data; the timeliness of regulatory approvals; the
continued demand for Arbutus’ assets; and the stability of economic
and market conditions. While Arbutus considers these assumptions to
be reasonable, these assumptions are inherently subject to
significant business, economic, competitive, market and social
uncertainties and contingencies, including uncertainties and
contingencies related to patent litigation matters.
Additionally, there are known and unknown risk
factors which could cause Arbutus’ actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements contained herein. Known risk factors
include, among others: anticipated pre-clinical studies and
clinical trials may be more costly or take longer to complete than
anticipated, and may never be initiated or completed, or may not
generate results that warrant future development of the tested
product candidate; Arbutus may elect to change its strategy
regarding its product candidates and clinical development
activities; Arbutus may not receive the necessary regulatory
approvals for the clinical development of Arbutus’ products;
economic and market conditions may worsen; uncertainties associated
with litigation generally and patent litigation specifically;
Arbutus and its collaborators may never realize the expected
benefits of the collaborations; and market shifts may require a
change in strategic focus.
A more complete discussion of the risks and
uncertainties facing Arbutus appears in Arbutus’ Annual Report on
Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’
continuous and periodic disclosure filings, which are available
at www.sedar.com and at www.sec.gov. All
forward-looking statements herein are qualified in their entirety
by this cautionary statement, and Arbutus disclaims any obligation
to revise or update any such forward-looking statements or to
publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future
results, events or developments, except as required by
law.Contact Information
Investors and MediaLisa M. CaperelliVice
President, Investor RelationsPhone: 215-206-1822Email:
lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024